- 1711.885
- -7.518-0.44%
Baird Adjusts Price Target on Laboratory Corp of America Holdings to $256 From $255, Keeps Outperform Rating
Argus Adjusts Price Target on Quest Diagnostics to $215 From $163, Keeps Buy Rating
Argus Raises Quest Diagnostics' Price Target to $163 From $155
Buy Rating Affirmed for Quest Diagnostics on Strong Earnings Visibility and Growth Prospects
TD Cowen: Maintaining the Charles River (CRL.US) rating, adjusted from holding to holding rating, and adjusted the target price from $260.00 to $228.00.
Charles River Analyst Ratings
TD Cowen Adjusts Price Target on Charles River Laboratories International to $228 From $260
Charles Rhyee Maintains Hold on Charles River Labs Amidst Revenue and Market Uncertainties
Analysts Offer Insights on Healthcare Companies: Charles River Labs (CRL), Plus Therapeutics (PSTV) and Argenx Se (ARGX)
Charles River Analyst Ratings
Baird Adjusts Price Target on Charles River Laboratories International to $270 From $282
Buy Rating on Charles River Labs Amidst Solid Q1 Performance and Positive Market Outlook
Catalent's Resilient Growth and Positive Outlook Reinforce Buy Rating
RBC Capital Sticks to Their Hold Rating for Catalent (CTLT)
Analysts Are Bullish on These Healthcare Stocks: IQVIA Holdings (IQV), CVS Health (CVS)
Stifel Nicolaus Keeps Their Buy Rating on IQVIA Holdings (IQV)
Stifel Adjusts Price Target on IQVIA Holdings to $288 From $294
UBS Adjusts Price Target on IQVIA Holdings to $295 From $300, Maintains Buy Rating
Truist Securities Maintains Buy on IQVIA Hldgs, Lowers Price Target to $292
Buy Rating Affirmed for IQVIA Holdings Amidst Strong Growth and Resilient Demand